Diabetology (BLOOD SUGAR) Part 2 with Dr. Mike Natter, MD

Episode Summary

Executive Summary: Allie Ward continues a diabetes-focused Q&A with endocrinologist and type 1 diabetic Dr. Mike Natter, covering blood sugar basics, stress and exercise effects, diagnosis thresholds, reactive and gestational hypoglycemia, insulin resistance, diet debates, diabetes tech, emergency response, and the crisis of insulin affordability. The episode mixes practical medical guidance with advocacy, emphasizing prevention, monitoring, and systemic access to care.

Main Topics: Blood sugar regulation, stress, and physiology (Priority: 5/5): Explains how stress activates the HPA axis, releases adrenaline/catecholamines, breaks down glycogen into glucose, and raises blood sugar—especially dangerous in type 1 diabetes without insulin. Diagnosis, prediabetes, and diabetes types (Priority: 5/5): Defines A1C and fasting glucose thresholds, distinguishes prediabetes from diabetes, and clarifies how type 1 and type 2 differ genetically and immunologically. Insulin resistance and type 2 diabetes prevention (Priority: 5/5): Describes insulin as a key and receptors as locks, links insulin resistance to lipotoxicity, inflammation, central adiposity, and recommends diet, exercise, and weight loss as first-line interventions. Exercise, hypoglycemia, and glucose management (Priority: 4/5): Discusses how exercise increases glucose uptake and can lower insulin needs, plus how reactive hypoglycemia occurs and how frequent mixed meals can help stabilize blood sugar. Diabetes technology and monitoring (Priority: 4/5): Covers insulin pumps, CGMs, closed-loop systems, and how these tools reduce cognitive load and improve time-in-range, while noting current limitations and device maintenance. Gestational diabetes and pregnancy risks (Priority: 4/5): Explains that placental hormones can drive insulin resistance during pregnancy and that gestational diabetes increases later type 2 risk, requiring tight medical management. Insulin pricing, access, and advocacy (Priority: 5/5): Highlights the severe affordability crisis in the U.S., insulin rationing, preventable deaths, historical context around Banting's patent, and the need for policy intervention.

Key Arguments: Stress raises blood sugar through the HPA axis and glycogen breakdown; type 1 diabetics lack insulin to move that glucose into cells, so stress can cause harmful hyperglycemia. Prediabetes is typically defined by A1C 5.7-6.4% and diabetes at 6.5% or higher; fasting glucose and oral glucose tolerance tests can also be used. Type 2 diabetes has a strong hereditary component but is also heavily shaped by environment; genetics may load the gun and environment pulls the trigger. Insulin resistance is not just about eating sugar; it is linked to saturated fat, processed meats, lipotoxicity, inflammation, and fat deposition in liver, pancreas, and muscle. Weight loss, exercise, and dietary changes can markedly improve or even reverse type 2 diabetes; bariatric surgery can be especially effective in some cases. Plant-based diets are presented as more evidence-supported than keto/paleo-style high-meat diets for diabetes and cardiovascular risk reduction. Continuous glucose monitors and insulin pumps, especially closed-loop systems, materially improve diabetes management by reducing lows, highs, and daily mental burden. In emergencies, bystanders should call 911 first; for suspected hypoglycemia, glucagon or cheek-applied frosting can help if the person is unresponsive, while insulin should not be given if the person may instead be in DKA. The insulin affordability problem is a public health crisis; rationing insulin can lead to death, and government action is needed to reduce prices.

Data Points: A1C normal range: 4% to 5.5/5.6% - Used to describe average blood sugar over ~3 months via hemoglobin glycosylation. Prediabetes A1C range: 5.7% to 6.4% - Standard U.S. threshold for prediabetes. Diabetes A1C threshold: 6.5% and above - Diagnostic cutoff mentioned for diabetes. Fasting glucose threshold: above 126 mg/dL (twice) - Another diagnostic criterion for diabetes. Blood sugar record at diagnosis: 1,600 mg/dL - Dr. Natter’s own reported blood glucose at diagnosis. Low blood sugar example: 60s mg/dL - His blood glucose dropped into the 60s on the recording day. Very low A1Cs seen in severe cases: 18%-19% - Examples of extremely poor control, implying average glucose around 500 mg/dL. Blood cell turnover: ~120 days - Explains why A1C reflects roughly the prior 3 months. Gestational diabetes duration: transient during pregnancy - Can resolve after pregnancy but raises future type 2 risk. Insulin patent sale: $1 - Frederick Banting sold the insulin patent for a dollar. Insulin price increase: more than 400% - Describes U.S. insulin price inflation over roughly a decade. Monthly insulin cost example: about $600/month - Assuming 1-2 vials per month at roughly $300 each. Insulin vial price: about $300 per vial - Current out-of-pocket cost cited in the episode. Diabetic alert dog cost: up to $20,000 - Estimated cost of a fully trained service dog. CGM change interval: every 5 days - Dr. Natter’s current continuous glucose monitor replacement schedule. Pump change interval: every 3-4 days - Typical insulin pump infusion set/reservoir maintenance interval. Implantable CGM lifespan: 6 months to 1 year - Future tech described as under development. Exercise effect on insulin needs: can reduce insulin requirements substantially - Especially in highly active or marathon-level patients.

Pivotal Quotes: "Genetics will load the gun and environment pulls the trigger." — Dr. Mike Natter: Explaining that diabetes risk is shaped by heredity plus lifestyle/environment. "Diabetes sucks. It really sucks." — Dr. Mike Natter: Summing up the constant burden, complications, and 24/7 management of the disease. "I want them to live longer and healthier and feel good." — Dr. Mike Natter: Describing the motive behind weight-loss counseling and diabetic care.

Implications: The episode teaches practical diabetes literacy while underscoring that access, affordability, and early monitoring are lifesaving. It also points to a future of smarter devices and possibly curative therapies, but only if systemic barriers are addressed.